Stock Quote

A Swiss biotech firm developing a Covid treatment has seen its share price soar 38,000% this year

Swiss biotech firm Relief Therapeutics has seen its share price climb by nearly 38,000% so far this year, as it develops a drug focused on respiratory failure arising from severe Covid-19.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.